| Gender | Male |
| (%) | 64 (73%) |
| Cirrhosis |
|
| (%) | 84(95%) |
| Etiology |
|
| HCV | 60 (68%) |
| Alcohol | 10 (11%) |
| HBV | 8 (9%) |
| NASH | 4 (5%) |
| Others (hemochromatosis/AIH/fibrolamellar/schistosomiasis) | 6 (7%) |
| Prior treatment to Sorafenib |
|
| TACE | 37 (42%) |
| RFA/PEI | 6 (7%) |
| Resection | 7 (8%) |
| No treatment | 38 (43%) |
| ChildPugh |
|
| A | 80 (91%) |
| B | 8 (9%) |
| ECOG-Perfomance Status |
|
| 0 | 52 (59%) |
| 1 | 30 (34%) |
| 2 | 6 (7%) |
| Alphafetoprotein |
|
| 0 - 100 | 41 (47%) |
| >101 | 47 (53%) |
| BCLC Staging System |
|
| B | 16 (18%) |
| C | 72 (82%) |
| Number of nodules |
|
| 1 | 24 (27%) |
| 2 | 9 (10%) |
| 3 | 12 (14%) |
| Multifocal | 43 (49%) |
| Diameter of the nodules |
|
| variation | 8 a 190 mm |
| average | 65.4 mm |
| median | 64.2 mm |
| Metastasis |
|
| Yes | 42 (48%) |
| No | 46 (52%) |
| Vascular Invasion |
|
| Yes | 61 (69%) |
| No | 27 (31%) |